ZVRA — Zevra Therapeutics, Inc.

Summary of Zevra's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $26.1 million, with $22.4 million attributed to MIPLYFFA.
• Operating Expenses: $20.4 million, down $6.8 million year-over-year.
• R&D Expenses: $3.4 million, a decrease of $7.5 million compared to Q3 2024.
• SG&A Expenses: $16.9 million, an increase of $700,000 year-over-year.
• Net Loss: $500,000, or $0.01 per share, significantly improved from a net loss of $33.2 million in Q3 2024.
• Cash Position: $230.4 million, up $12.7 million from Q2 2025, bolstered by warrant exercises and interest income.

2. Strategic Updates and Business Highlights

• MIPLYFFA Performance: Continued strong performance with 8 new prescription enrollments in Q3, totaling 137 since launch. The drug is the first approved treatment for Niemann-Pick disease type C (NPC) in the U.S.
• Market Expansion: Plans to expand into the European market, with a Marketing Authorization Application (MAA) filed and under review by the European Medicines Agency.
• OLPRUVA Strategy: Sales and marketing efforts for OLPRUVA are being scaled back due to challenges in a mature UCD market, reallocating resources to MIPLYFFA.
• Pipeline Development: Active recruitment in the Phase III DiSCOVER trial for Celiprolol targeting Vascular Ehlers-Danlos Syndrome (VEDS), with 44 patients enrolled to date.

3. Forward Guidance and Outlook

• Growth Potential: Anticipation of continued growth for MIPLYFFA in the U.S. and potential approval in Europe, with confidence in the expanded data set supporting the MAA.
• Financial Position: Management believes current financial resources are sufficient to execute strategic priorities without needing to access capital markets in the near term.

4. Bad News, Challenges, or Points of Concern

• OLPRUVA's Market Performance: Despite efforts, OLPRUVA has not penetrated the UCD market effectively, leading to a strategic retreat in promotional activities.
• Gross to Net Adjustments: A true-up of $1.2 million due to redesigns in Medicare Part D rebates impacted Q3 net revenue, indicating potential volatility in revenue recognition.
• Patient Enrollment Stability: While new enrollments are promising, there is concern about reaching a steady state in patient enrollment forms, with varying quarterly results.

5. Notable Q&A Insights

• Patient Identification: Management highlighted ongoing efforts to identify previously undiagnosed patients through disease awareness campaigns and partnerships with genetic testing collaborators.
• Refill Rates: The majority of patients are reportedly receiving refills, with a significant percentage of covered lives at 66%.
• European Pricing Strategy: Discussions around pricing for MIPLYFFA in Europe are ongoing, with expectations for favorable market dynamics due to existing treatment precedents.
• KP1077 Strategic Options: The company remains open to strategic alternatives regarding KP1077, indicating ongoing discussions but no specific plans disclosed.

Overall, Zevra demonstrated strong financial improvement and strategic momentum in Q3 2025, particularly with MIPLYFFA, while facing challenges with OLPRUVA and navigating market dynamics for future growth.